The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2024 | Early interception in SMM & novel agents being explored
In this discussion, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, Kwee Yong, PhD, FRCP, FRCPath, University College London, London, UK, and Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, discuss the possibility of early interception in smoldering multiple myeloma (SMM). The experts share insights into ongoing trials exploring novel agents in SMM, including the ImmunoPRISM trial (NCT05469893), and further discuss the importance of patient preference when making treatment decisions, as well as the need to better understand the immune response in SMM. This session was filmed at IBC 2024, held in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
